Skip to main content

Bioventus Inc.

BVS
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001665988

No open-market purchases or sales by Bioventus Inc. insiders were filed in the last 90 days; 156 institutions reported holding it in 13F filings for Q2 2026, worth $566.0M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +2 vs. previous quarter
156
13F valueReported value at the end of Q2 2026
$566.0M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding BVS, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BVS at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Bioventus Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 13, 2026 (view filing)Mar 112 daysMcMurry-Heath MichelleDirectorSSaleClass A Common Stock−12.0K$8.79−$105.5K−21.1%45.0K after
Dec 8, 2025 (view filing)Dec 44 daysNohra Guy PDirectorSSaleClass A Common Stock−10.0K$7.57−$75.7K−7.9%116.6K after
Nov 10, 2025 (view filing)Nov 73 daysMcMurry-Heath MichelleDirectorSSaleClass A Common Stock−17.7K$7.42−$131.3K−23.7%57.0K after
Apr 15, 2025 (view filing)Apr 114 daysSingleton Mark LeonardSVP & CFOSSaleClass A Common Stock−3.88K$7.57−$29.3K−2.7%141.1K after10b5-1
Apr 15, 2025 (view filing)Apr 114 daysD'Adamio AnthonySVP & General CounselSSaleClass A Common Stock−2.96K$7.57−$22.4K−2.2%131.4K after10b5-1
Apr 15, 2025 (view filing)Apr 114 daysChurch Katrina JSVP & Chief Compliance OfficerSSaleClass A Common Stock−1.28K$7.57−$9.71K−2.3%55.6K after10b5-1
Mar 25, 2025 (view filing)Mar 241 daySingleton Mark LeonardSVP & CFOSSaleClass A Common Stock−5.48K$9.79−$53.6K−4.0%132.0K after10b5-1
Mar 18, 2025 (view filing)Mar 171 dayChurch Katrina JSVP & Chief Compliance OfficerSSaleClass A Common Stock−1.02K$9.75−$9.93K−1.9%52.5K after10b5-1
Mar 18, 2025 (view filing)Mar 171 dayD'Adamio AnthonySVP & General CounselSSaleClass A Common Stock−2.62K$9.75−$25.5K−2.1%124.4K after10b5-1
Feb 20, 2025 (view filing)Feb 182 daysSingleton Mark LeonardSVP & CFOSSaleClass A Common Stock−6.50K$10.19−$66.2K−5.2%118.8K after10b5-1

Top 10 13F holders, Q2 2026

The largest institutional positions in Bioventus Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 156 holders
Institutions holding BVS in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Essex Woodlands Management, Inc.13,021,324$122.9M48.35%00.0%Unchanged
Nantahala Capital Management, LLC12,000,558$113.3M3.43%+5,878,155+96.0%Added
Juniper Investment Company, LLC6,939,357$65.5M17.35%00.0%Unchanged
BlackRock, Inc.3,435,914$32.4M0.00%+302,373+9.6%Added
Royce & Associates LP1,833,212$17.3M0.14%+291,930+18.9%Added
Vanguard Capital Management LLC1,751,678$16.5M0.00%+36,971+2.2%Added
Geode Capital Management, LLC1,365,716$12.9M0.00%+197,469+16.9%Added
American Century Companies Inc1,353,415$12.8M0.01%+733,612+118.4%Added
Dimensional Fund Advisors LP1,128,465$10.7M0.00%+255,327+29.2%Added
State Street Corp1,104,878$10.4M0.00%+116,511+11.8%Added